EN
中
CLOSE
Lumosa Home
About Lumosa
Overview
Mission and Milestones
Lumosa Team
Awards
Translational Research /
Licensing Assessment
R&D Pipeline
Licensing Opportunities
News Center
Investors
Join Lumosa
Contact Lumosa
4th Floor, No. 3-2, Park Street, Nangang District, Taipei, 11503, Taiwan
TEL
:
+886-2-26557918
FAX
:
+886-2-26557919
Pipeline
Licensing
News
Investors
中文
MENU
LANGUAGE
中
EN
MENU
Better Therapy Brighter Outlook
About Lumosa
Explore
reSEARCH & DEVELOPMENT
In-Licensing
Detail
R&D Projects
Detail
Out-Licensing
Detail
Read More
About Lumosa
Investors
Contact Us
Join Lumosa
R&D Pipeline
LT-1001 (Naldebain)
LT-3001
LT-2003
LT-5001
News Center
12
31
2019
,
Tue
Lumosa Received LT5001 IND Approval from TFDA for the Treatment of Uremic Pruritus
Phase Ib/II Trial will Commence Soon in Taiwan
Detail
12
02
2019
,
Mon
Lumosa Licensed LT1001 to Jemincare in China
Detail
11
26
2019
,
Tue
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection Lumosa to Initiate the Bridging Study in the US
Detail
11
06
2019
,
Wed
LT3001 China Region Out-Licensed to SHP
Detail
+
More News
Site Map
Home
About Lumosa
Translational Research/Licensing Assessment
R&D Pipeline
Licensing Opportunities
News Center
Investors
Join Lumosa
Contact Lumosa
+
Close
